Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neihulizumab in moderate to severe chronic plaque psoriasis
NCT02223039Phase 2Completed
- Sponsor
- AbGenomics
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of neihulizumab in plaque psoriasis, sponsored by AbGenomics. Started May 2014; status: completed.
02
Drugs
neihulizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02223039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223039.